Compare ORIO & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ORIO | NRSN |
|---|---|---|
| Founded | N/A | 2017 |
| Country | Canada | Israel |
| Employees | 188 | 16 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.3M | 26.5M |
| IPO Year | N/A | N/A |
| Metric | ORIO | NRSN |
|---|---|---|
| Price | $0.98 | $0.83 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 39.4K | ★ 143.3K |
| Earning Date | 03-12-2026 | 03-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $74.52 | N/A |
| Revenue Next Year | $5.07 | $583.67 |
| P/E Ratio | $4.93 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.90 | $0.63 |
| 52 Week High | $1.40 | $2.60 |
| Indicator | ORIO | NRSN |
|---|---|---|
| Relative Strength Index (RSI) | 37.85 | 51.83 |
| Support Level | N/A | $0.67 |
| Resistance Level | $1.11 | $0.86 |
| Average True Range (ATR) | 0.05 | 0.06 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 8.33 | 35.02 |
Orion Digital Corp is a financial technology company operating digital platforms across wealth and payments, supported by a consumer lending business in Canada. The Company's Wealth platform, Intelligent Investing, provides long-term investment solutions to the Canadian market. It also operates a consumer lending business in Canada. Its Payments business is conducted through its wholly owned subsidiary, which provides issuer processing, program management, and regulated payment orchestration services across Europe. The Company operates in Canada and Europe, with Canada generating the majority of its revenue.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.